Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 7/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.42 |
| ▸ | RXRA | P19793 | 3/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29333832 | 1.00 | NR1H2 (0.42) | NR1H2NR1H3RXRAUSP30TMEM97 | |
| SCHEMBL29333868 | 0.84 | UCHL1 (0.41) | USP30MALT1TSHRCCNCCDK8 | |
| SCHEMBL30855205 | 0.84 | UCHL1 (0.41) | USP30MALT1TSHRCCNCCDK8 | |
| SCHEMBL14829637 | 0.83 | NR1H2 (0.49) | NR1H2NR1H3RXRATMEM97SIGMAR1 | |
| SCHEMBL13749174 | 0.83 | NR1H2 (0.49) | NR1H2NR1H3RXRATMEM97SIGMAR1 | |
| SCHEMBL14829403 | 0.83 | NR1H2 (0.49) | NR1H2NR1H3RXRATMEM97SIGMAR1 | |
| SCHEMBL29333843 | 0.83 | MALT1 (0.36) | USP30MALT1TSHRGRM5CCNC | |
| SCHEMBL29333887 | 0.83 | MALT1 (0.39) | USP30MALT1TSHRGRM5CCNC | |
| SCHEMBL29333833 | 0.83 | MALT1 (0.39) | NR1H2NR1H3USP30MALT1TSHR | |
| SCHEMBL29333856 | 0.83 | MALT1 (0.39) | NR1H2NR1H3USP30MALT1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | NR1H2 55/4885NR1H3 71/4885RXRA 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.